Strong PSMA Expression by a Pituitary Macroadenoma on PSMA PET/CT

An 81-year-old man was found to have an elevated PSA, prompting a prostate biopsy that revealed Gleason grade 7 (3+4) prostate cancer. For staging purposes, an 18F-DCFPyL PSMA PET/CT was performed, which demonstrated focal uptake in the pituitary region corresponding to a suprasellar mass. Subsequent pituitary MRI confirmed the presence of a pituitary macroadenoma. The expanding global use of PSMA PET has increasingly revealed PSMA ligand uptake in a variety of non-prostatic benign and malignant conditions, creating false positive results. Our case highlights that pituitary macroadenoma may have strong PSMA expression and should be recognized as a potential imaging pitfall.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2025-12-19
DOI
https://doi.org/10.1097/rlu.0000000000006279
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Strong PSMA Expression by a Pituitary Macroadenoma on PSMA PET/CT

Sampanna Rayamajhi, Nasrin Ghesani, Mudassir Mumtaz, Busra Cangut et al.
Clinical Nuclear Medicine
Prostate Cancer Treatment and Research
article

Strong PSMA Expression by a Pituitary Macroadenoma on PSMA PET/CT

Sampanna Rayamajhi, Nasrin Ghesani, Mudassir Mumtaz, Busra Cangut, Ava Mohseny
article en

Abstract

An 81-year-old man was found to have an elevated PSA, prompting a prostate biopsy that revealed Gleason grade 7 (3+4) prostate cancer. For staging purposes, an 18F-DCFPyL PSMA PET/CT was performed, which demonstrated focal uptake in the pituitary region corresponding to a suprasellar mass. Subsequent pituitary MRI confirmed the presence of a pituitary macroadenoma. The expanding global use of PSMA PET has increasingly revealed PSMA ligand uptake in a variety of non-prostatic benign and malignant conditions, creating false positive results. Our case highlights that pituitary macroadenoma may have strong PSMA expression and should be recognized as a potential imaging pitfall.

Clinical Nuclear Medicine
Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 29%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Strong PSMA Expression by a Pituitary Macroadenoma on PSMA PET/CT — Sampanna Rayamajhi, Nasrin Ghesani, et al. · Clinical Nuclear Medicine (2025) | TGRS Research Map | TGRS